Key Insights

Highlights

Success Rate

98% trial completion (above average)

Published Results

103 trials with published results (44%)

Research Maturity

199 completed trials (85% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

1.7%

4 terminated out of 235 trials

Success Rate

98.0%

+11.5% vs benchmark

Late-Stage Pipeline

65%

153 trials in Phase 3/4

Results Transparency

52%

103 of 199 completed with results

Key Signals

103 with results98% success

Data Visualizations

Phase Distribution

214Total
Not Applicable (12)
P 1 (19)
P 2 (30)
P 3 (106)
P 4 (47)

Trial Status

Completed199
Unknown12
Recruiting6
Not Yet Recruiting6
Terminated4
Active Not Recruiting4

Trial Success Rate

98.0%

Benchmark: 86.5%

Based on 199 completed trials

Clinical Trials (235)

Showing 20 of 20 trials
NCT07492303Phase 1Not Yet Recruiting

A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)

NCT07446166Not ApplicableNot Yet RecruitingPrimary

TETANUS Antibody Detection in Saliva Study

NCT07444502Completed

Safety Monitoring of Boostagen® Vaccine in Thailand

NCT07418372Phase 1Not Yet Recruiting

Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine

NCT07149454Phase 1Enrolling By InvitationPrimary

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection

NCT07358910Recruiting

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

NCT07347938Not Yet RecruitingPrimary

A Phase 4 Study to Evaluate the Effectiveness and Safety of Siltartoxatug Injection for Tetanus Prophylaxis Following Injury

NCT03891758Phase 3CompletedPrimary

Confirmatory Study of BK1310 in Healthy Infants

NCT07107932RecruitingPrimary

A Registry: Siltartoxatug Injection for Tetanus Prophylaxis Following Injury

NCT02118961Phase 3Completed

Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents

NCT06588530Phase 4Completed

PFAS Exposure and Immune Response to Vaccination in Adults

NCT05625477Phase 2CompletedPrimary

Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers

NCT05091619Phase 3Active Not Recruiting

A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed

NCT06947499Phase 2Recruiting

A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series

NCT03589768Phase 2Completed

Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants

NCT06939777Phase 1Not Yet RecruitingPrimary

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants

NCT06056050Phase 1Active Not Recruiting

A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)

NCT06708286Phase 2Active Not Recruiting

A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)

NCT06120751Phase 3CompletedPrimary

A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over

NCT06123663Phase 1CompletedPrimary

A Study to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over

Scroll to load more

Research Network

Activity Timeline